Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Investment analysts at Noble Financial issued their FY2026 earnings per share estimates for shares of Greenwich LifeSciences in a research report issued on Wednesday, November 18th. Noble Financial analyst R. Leboyer expects that the company will post earnings per share of ($1.49) for the year. The consensus estimate for Greenwich LifeSciences' current full-year earnings is ($1.29) per share. Noble Financial also issued estimates for Greenwich LifeSciences' Q4 2026 earnings at ($0.43) EPS, Q1 2027 earnings at ($0.49) EPS, Q2 2027 earnings at ($0.51) EPS, Q3 2027 earnings at ($0.55) EPS, Q4 2027 earnings at ($0.59) EPS and FY2027 earnings at ($2.14) EPS.
GLSI has been the topic of a number of other reports. HC Wainwright raised their price target on Greenwich LifeSciences from $69.00 to $70.00 and gave the company a "buy" rating in a report on Wednesday. Weiss Ratings raised Greenwich LifeSciences from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Greenwich LifeSciences presently has an average rating of "Hold" and an average price target of $70.00.
Get Our Latest Stock Analysis on Greenwich LifeSciences
Greenwich LifeSciences Trading Down 3.8%
NASDAQ GLSI opened at $19.79 on Friday. The company has a 50-day moving average price of $16.78 and a two-hundred day moving average price of $20.82. The stock has a market cap of $290.52 million, a price-to-earnings ratio of 0.00 and a beta of 1.57. Greenwich LifeSciences has a 52 week low of $7.78 and a 52 week high of $34.10.
Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.06).
Hedge Funds Weigh In On Greenwich LifeSciences
Institutional investors have recently bought and sold shares of the stock. Ancora Advisors LLC raised its holdings in shares of Greenwich LifeSciences by 101.2% during the third quarter. Ancora Advisors LLC now owns 21,610 shares of the company's stock valued at $390,000 after acquiring an additional 10,870 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Greenwich LifeSciences by 44.4% in the third quarter. Goldman Sachs Group Inc. now owns 56,793 shares of the company's stock valued at $1,025,000 after purchasing an additional 17,464 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Greenwich LifeSciences in the second quarter worth $11,398,000. Deutsche Bank AG acquired a new position in Greenwich LifeSciences during the second quarter valued at $126,000. Finally, Bank of New York Mellon Corp purchased a new stake in Greenwich LifeSciences in the 2nd quarter worth about $1,124,000. Hedge funds and other institutional investors own 4.16% of the company's stock.
Key Stories Impacting Greenwich LifeSciences
Here are a few of the latest stories about GLSI:
- Positive Sentiment: HC Wainwright raised its price target to $70 from $69 and kept its Buy rating, signaling continued confidence despite the forecast reductions. Greenwich LifeSciences stock gets price target boost from HC Wainwright
- Neutral Sentiment: Noble Financial issued forecasts for losses of $1.49 per share in FY2026 and $2.14 in FY2027. These are new estimates rather than reported results or announced changes to its prior forecasts.
- Negative Sentiment: HC Wainwright lowered its EPS forecasts across late 2026 and 2027. Its FY2026 estimate moved to a loss of $1.46 per share from $1.29, while its FY2027 forecast fell to a loss of $1.46 from $1.17. The wider expected losses are the clearest near-term negative in the updates.
About Greenwich LifeSciences
(
Get Free Report)
Greenwich LifeSciences, Inc. is a clinical-stage biotechnology company developing immunotherapies intended to reduce the risk of breast cancer recurrence. The company's work centers on GP2, an investigational peptide-based vaccine designed for patients with HER2/neu-positive breast cancer who have completed standard treatment. GP2 is intended to stimulate an immune response against cancer cells expressing HER2/neu and is administered with the immune-system stimulant GM-CSF. Greenwich LifeSciences is evaluating the candidate in clinical trials; it does not have an approved commercial product.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Greenwich LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Greenwich LifeSciences wasn't on the list.
While Greenwich LifeSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.